혈액종양내과 김기현 교수

학력
2008.08	서울대학교 대학원 의학과 (박사)
2000.02	중앙대학교 대학원 의학과 (석사)
1991.02	서울대학교 의과대학 졸업 (의학사)
1987.02	서울대학교 자연과학대학 의예과 수료

경력
2014.09 ~현재	성균관대학교 의과대학 내과학 교수
2008.09 ~ 2014.08	성균관대학교 의과대학 내과학 부교수
2002.03 ~ 2008.08	성균관대학교 의과대학 내과학 조교수
2001.03 ~ 2002.02	삼성서울병원 혈액종양내과 전문의
2000.03 ~ 2001.02	분당제생병원 내과 전문의
1999.03 ~ 2000.02	삼성서울병원 혈액종양내과 전임의
1999.03	내과 전문의 자격 취득
1995.03 ~ 1999.02	삼성서울병원 내과 레지던트 과정 수료
1991.03 ~ 1992.02	서울대학교병원 인턴과정 수료

BMC MED IMAGING 2023 10.1186/s12880-023-01054-x Direct comparison of diagnostic and clinical values between Tc-99 m DPD and Tc-99 m PYP scintigraphy in patients with cardiac amyloidosis Park, YJ; Lee, JH; Kim, D; Choi, JO; Kim, SJ; Kim, K; Choi, JY

View PubMed

ANN HEMATOL 2023 10.1007/s00277-023-05308-0 Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015) Kim, M; Lee, JJ; Min, CK; Lee, JY; Jo, JC; Yoon, SS; Lim, SN; Do, YR; Kim, K; Lee, JH; Yoo, KH; Bae, SH; Yi, JH; Jung, J; Eom, HS; Jung, SH

View PubMed

CL LYMPH MYELOM LEUK 2023 10.1016/j.clml.2023.02.009 Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study Fu, WJ; Bang, SM; Huang, HH; Kim, K; Li, W; An, G; Lee, JJ; Cai, Z; Jin, J; Wang, YF; Lin, TL; Chim, CS; Qi, M; Wang, JP; Lu, XL; Song, Y; Jia, B; Yang, X; Liu, WY; Zhou, TY; Yin, L; Li, YA; Zhang, RY; Hou, J; Wang, JX

View PubMed

SCI REP-UK 2023 10.1038/s41598-023-34653-3 Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis Lee, H; Hyun, SH; Cho, YS; Moon, SH; Choi, JY; Kim, K; Lee, KH

View PubMed

INT J HEMATOL 2023 10.1007/s12185-022-03525-3 A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K

View PubMed

AM J HEMATOL 2023 10.1002/ajh.26866 Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice Sanchorawala, V; Wechalekar, AD; Kim, K; Schonland, SO; Landau, HJ; Kwok, F; Suzuki, K; Dispenzieri, A; Merlini, G; Comenzo, RL; Cherepanov, D; Hayden, VC; Kumar, A; Labotka, R; Faller, DV; Kastritis, E

View PubMed

KOREAN CIRC J 2023 10.4070/kcj.2022.0356 A Novel Transthyretin Gene Mutation in Hereditary Transthyretin Amyloidosis: A Case Series of Met13dup Patients Jeon, K; Kim, D; Park, M; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES

View PubMed

BLOOD CANCER J 2023 10.1038/s41408-023-00797-8 Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study Martin, T; Dimopoulos, MA; Mikhael, J; Yong, K; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Casca, F; Mace, S; Risse, ML; Moreau, P

View PubMed

CANCER RES TREAT 2023 10.4143/crt.2022.952 Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study Jung, J; Kim, K; Jung, SH; Yoon, SS; Lee, JH; Kim, JS; Shin, HJ; Bang, SM; Sohn, SK; Suh, C; Yoon, DH; Kong, SY; Min, CK; Eom, HS; Korean Multiple Myeloma Working Party

View PubMed

ANN HEMATOL 2023 10.1007/s00277-023-05090-z Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA Suzuki, K; Wechalekar, AD; Kim, K; Shimazaki, C; Kim, JS; Ikezoe, T; Min, CK; Zhou, FD; Cai, Z; Chen, XN; Iida, S; Katoh, N; Fujisaki, T; Shin, HJ; Tran, N; Qin, X; Vasey, SY; Tromp, B; Weiss, BM; Comenzo, RL; Kastritis, E; Lu, J

View PubMed

CL LYMPH MYELOM LEUK 2023 10.1016/j.clml.2022.10.010 Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea Kim, HR; Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K

View PubMed

INT J HEMATOL 2023 10.1007/s12185-022-03479-6 Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma Lee, JH; Kim, SH; Kim, HR; Min, CK; Lee, JJ; Shin, HJ; Jo, JC; Lee, JY; Moon, JH; Kim, K

View PubMed

NEPHROL DIAL TRANSPL 2023 10.1093/ndt/gfad016 Acute kidney injury in bortezomib-treated patients with multiple myeloma Song, SM; Jeon, J; Jang, HR; Kim, K; Huh, W; Kim, YG; Lee, JE

View PubMed

BONE MARROW TRANSPL 2022 10.1038/s41409-022-01818-z Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909) Jung, SH; Min, CK; Lee, JH; Mun, YC; Bang, SM; Yoon, DH; Lee, HS; Kim, K; Lee, JJ

View PubMed

BLOOD CANCER J 2022 10.1038/s41408-022-00755-w Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party Jung, SH; Kim, K; Yoon, SE; Moon, JH; Kim, D; Kim, HJ; Kim, MK; Ha Kim, K; Lee, HJ; Lee, JH; Kim, SH; Yoo, KH; Lee, JH; Lee, JJ

View PubMed

AMYLOID 2022 10.1080/13506129.2022.2082866 Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis Kwon, S; Jeong, WK; Park, JH; Kim, J; Cho, EB; Seok, JM; Kim, SJ; Kim, K; Jeon, ES; Min, JH; Kim, BJ

View PubMed

INT J HEMATOL 2022 10.1007/s12185-022-03378-w Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis Kim, K; Min, CK; Koh, Y; Ishizawa, K; Kim, SH; Ito, S; Tanaka, J; Uchiyama, M; Kawano, Y; Kim, JS; Moreau, P; Martin, T; Dong, Y; Risse, ML; Suzuki, K

View PubMed

J HEMATOL ONCOL 2022 10.1186/s13045-022-01374-5 Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease Byun, JM; Min, CK; Kim, K; Bang, SM; Lee, JJ; Kim, JS; Yoon, SS; Koh, Y

View PubMed

ANN LAB MED 2022 10.3343/alm.2022.42.5.558 Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma Kim, HY; Yoo, IY; Lim, DJ; Kim, HJ; Kim, SH; Yoon, SE; Kim, SJ; Cho, D; Kim, K

View PubMed

BLOOD ADV 2022 10.1182/bloodadvances.2021006713 Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma Martin, T; Mikhael, J; Hajek, R; Kim, K; Suzuki, K; Hulin, C; Garg, M; Quach, H; Sia, H; George, A; Konstantinova, T; Risse, ML; Asset, G; Mace, S; van de Velde, H; Moreau, P

View PubMed

CL LYMPH MYELOM LEUK 2022 10.1016/j.clml.2022.04.005 Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis Sunami, K; Ikeda, T; Huang, SY; Wang, MC; Koh, Y; Min, CK; Yeh, SP; Matsumoto, M; Uchiyama, M; Iyama, S; Shimazaki, C; Lee, JH; Kim, K; Kaneko, H; Kim, JS; Lin, TL; Campana, F; Tada, K; Iida, S; Suzuki, K

View PubMed

FRONT ONCOL 2022 10.3389/fonc.2022.959949 Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study) Song, GY; Jung, SH; Kim, JS; Eom, HS; Moon, JH; Yhim, HY; Kim, K; Min, CK; Lee, JJ; Korean Multiple Myeloma Working Party

View PubMed

INT J HEMATOL 2022 10.1007/s12185-022-03332-w Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805) Kim, K; Kim, JS; Yoon, SS; Yoon, DH; Eom, HS; Lee, JJ; Yim, HW; Park, M; Lee, H; Min, CK

View PubMed

FRONT CARDIOVASC MED 2022 10.3389/fcvm.2022.904878 Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis Bak, M; Kim, D; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

View PubMed

ANN HEMATOL 2022 10.1007/s00277-022-04776-0 Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma Chu, TH; Jung, SH; Kim, K; Lee, JH; Mun, YC; Bang, SM; Yoon, DH; Lee, HS; Min, CK; Lee, JJ

View PubMed

AM J HEMATOL 2022 10.1002/ajh.26536 Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone +/- daratumumab: Results from the ANDROMEDA study Sanchorawala, V; Palladini, G; Minnema, MC; Jaccard, A; Lee, HC; Gibbs, S; Mollee, P; Venner, C; Lu, J; Schonland, S; Gatt, M; Suzuki, K; Kim, K; Cibeira, MT; Beksac, M; Libby, E; Valent, J; Hungria, V; Wong, SW; Rosenzweig, M; Bumma, N; Chauveau, D; Gries, KS; Fastenau, J; Tran, NP; Qin, X; Vasey, SY; Weiss, BM; Vermeulen, J; Ho, KF; Merlini, G; Comenzo, RL; Kastritis, E; Wechalekar, AD

View PubMed

BRIT J HAEMATOL 2022 10.1111/bjh.17898 Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma Jung, SH; Lee, JJ; Song, GY; Lee, HS; Kim, SJ; Yoon, SE; Kim, K

View PubMed

CURR PROB CANCER 2022 10.1016/j.currproblcancer.2021.100788 Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features Yoo, KH; Yoon, DH; Kang, HJ; Lee, WS; Kim, K; Kim, JS; Kim, JA; Kim, SH; Kwak, JY; Kim, YS; Min, CK; Lee, JJ; Yoon, SS; Suh, C; Baz, R; Lee, JH

View PubMed

CURR PROB CANCER 2022 10.1016/j.currproblcancer.2021.100786 Limite d b enefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea Byun, JM; Kim, SA; Koh, Y; Shin, DY; Kwon, JH; Kim, JS; Kim, K; Min, CK; Eom, HS; Lee, JJ; Bang, SM; Yoon, SS

View PubMed

LEUKEMIA 2022 10.1038/s41375-021-01317-y A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis Dispenzieri, A; Kastritis, E; Wechalekar, AD; Schonland, SO; Kim, K; Sanchorawala, V; Landau, HJ; Kwok, F; Suzuki, K; Comenzo, RL; Berg, D; Liu, GH; Kumar, A; Faller, DV; Merlini, G

View PubMed

ESC HEART FAIL 2021 10.1002/ehf2.13604 Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis Kim, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES

View PubMed

BLOOD CANCER J 2021 10.1038/s41408-021-00577-2 Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT Cho, HJ; Jung, SH; Jo, JC; Lee, YJ; Yoon, SE; Park, SS; Kim, DY; Shin, HJ; Mun, YC; Yi, JH; Kim, HJ; Kim, DJ; Lee, HS; Bae, SH; Hong, CM; Jeong, SY; Min, JJ; Sohn, SK; Min, CK; Kim, K; Lee, JJ; Moon, JH

View PubMed

INT J HEMATOL 2021 10.1007/s12185-021-03204-9 Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial Suzuki, K; Min, CK; Kim, K; Lee, JJ; Shibayama, H; Ko, PS; Huang, SY; Li, SS; Ding, BF; Khurana, M; Iida, S

View PubMed

ANAL CHEM 2021 10.1021/acs.analchem.1c01722 tipNrich: A Tip-Based N-Terminal Proteome Enrichment Method Lee, S; Ju, S; Kim, SJ; Choi, JO; Kim, K; Kim, D; Jeon, ES; Lee, C

View PubMed

J CLIN APHERESIS 2021 10.1002/jca.21924 Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34(+) cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation Kim, SM; Kim, HY; Kim, SJ; Jang, JH; Kim, K; Kim, WS; Jung, CW; Cho, D; Kang, ES

View PubMed

SUPPORT CARE CANCER 2021 10.1007/s00520-021-06017-y Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma Kim, SJ; Kang, D; Park, Y; Mun, YC; Kim, K; Kim, JS; Min, CK; Cho, J

View PubMed

BRIT J HAEMATOL 2021 10.1111/bjh.17541 Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy Quach, H; Nooka, A; Samoylova, O; Venner, CP; Kim, K; Facon, T; Spencer, A; Usmani, SZ; Grosicki, S; Suzuki, K; Delimpasi, S; Weisel, K; Obreja, M; Zahlten-Kumeli, A; Mateos, MV

View PubMed

ANN HEMATOL 2021 10.1007/s00277-021-04407-0 Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial Lee, JH; Park, Y; Kang, KW; Lee, JJ; Lee, HS; Eom, HS; Do, YR; Kim, JS; Yoon, SS; Shin, DY; Koh, Y; Kim, KH; Lee, WS; Jo, JC; Lee, YJ; Lee, JY; Kim, DS; Shim, H; Chang, MH; Kim, SH; Min, CK

View PubMed

NEW ENGL J MED 2021 10.1056/NEJMoa2028631 Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Kastritis, E; Palladini, G; Minnema, MC; Wechalekar, AD; Jaccard, A; Lee, HC; Sanchorawala, V; Gibbs, S; Mollee, P; Venner, CP; Lu, J; Schonland, S; Gatt, ME; Suzuki, K; Kim, K; Cibeira, MT; Beksac, M; Libby, E; Valent, J; Hungria, V; Wong, SW; Rosenzweig, M; Bumma, N; Huart, A; Dimopoulos, MA; Bhutani, D; Waxman, AJ; Goodman, SA; Zonder, JA; Lam, S; Song, K; Hansen, T; Manier, S; Roeloffzen, W; Jamroziak, K; Kwok, F; Shimazaki, C; Kim, JS; Crusoe, E; Ahmadi, T; Tran, NP; Qin, X; Vasey, SY; Tromp, B; Schecter, JM; Weiss, BM; Zhuang, SH; Vermeulen, J; Merlini, G; Comenzo, RL

View PubMed

JACC CARDIOVASC IMAGING 2021 Association of Left Ventricular Global Longitudinal Strain With Cardiac Amyloid Load in Light Chain Amyloidosis Kim¹, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES

View PubMed

LANCET 2021 10.1016/S0140-6736(21)00592-4 Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Moreau¹, P; Dimopoulos, MA; Mikhael, J; Yong, K; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Risse, ML; Asset, G; Mace, S; Martin, T

View PubMed

LEUKEMIA 2021 10.1038/s41375-021-01317-y A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis Dispenzieri¹, A; Kastritis, E; Wechalekar, AD; Schonland, SO; Kim, K; Sanchorawala, V; Landau, HJ; Kwok, F; Suzuki, K; Comenzo, RL; Berg, D; Liu, GH; Kumar, A; Faller, DV; Merlini, G

View PubMed

BRIT J HAEMATOL 2021 10.1111/bjh.17541 Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy Quach¹, H; Nooka, A; Samoylova, O; Venner, CP; Kim, K; Facon, T; Spencer, A; Usmani, SZ; Grosicki, S; Suzuki, K; Delimpasi, S; Weisel, K; Obreja, M; Zahlten-Kumeli, A; Mateos, MV

View PubMed

KOREAN J INTERN MED 2021 10.3904/kjim.2019.367 Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia Cho¹, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ

View PubMed

J CLIN MED 2021 10.3390/jcm10071376 Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Mycobacterium tuberculosis Infections in Tertiary Care Setting? Jung¹, J; Jhun, BW; Jeong, M; Yoon, SJ; Huh, HJ; Jung, CW; Kim, K; Park, JB; Kim, DJ; Huh, W; Jang, HR; Kim, YH; Hong, SN; Chung, DR; Kang, ES

View PubMed

J CANCER 2021 10.7150/jca.55553 Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis Lee¹, JY; Ryu, D; Lim, SW; Ryu, KJ; Choi, ME; Yoon, SE; Kim, K; Park, C; Kim, SJ

View PubMed

SUPPORT CARE CANCER 2021 10.1007/s00520-021-06017-y Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma Kim¹, SJ; Kang, D; Park, Y; Mun, YC; Kim, K; Kim, JS; Min, CK; Cho, J

View PubMed

ANN HEMATOL 2021 10.1007/s00277-021-04405-2 Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study Iida¹, S; Ishikawa, T; Min, CK; Kim, K; Yeh, SP; Usmani, SZ; Mateos, MV; Nahi, H; Heuck, C; Qin, X; Parasrampuria, DA; Gries, KS; Qi, M; Bahlis, N; Ito, S

View PubMed

ANN HEMATOL 2021 10.1007/s00277-021-04407-0 Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial Lee¹, JH; Park, Y; Kang, KW; Lee, JJ; Lee, HS; Eom, HS; Do, YR; Kim, JS; Yoon, SS; Shin, DY; Koh, Y; Kim, KH; Lee, WS; Jo, JC; Lee, YJ; Lee, JY; Kim, DS; Shim, H; Chang, MH; Kim, SH; Min, CK

View PubMed

BRIT J HAEMATOL 2020 10.1111/bjh.17071 Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy Park¹, SS; Byun, JM; Yoon, SS; Kim, K; Jung, SH; Lee, JJ; Min, CK

View PubMed

BLOOD CANCER J 2020 10.1038/s41408-020-00375-2 Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma a cytogenetic subgroup analysis of POLLUX Kaufman¹, JL; Dimopoulos, MA; White, D; Benboubker, L; Cook, G; Leiba, M; Morton, J; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Sutherland, HJ; Magen, H; Iida, S; Kim, JS; Prince, HM; Cochrane, T; Oriol, A; Bahlis, NJ; Chari, A; O'Rourke, L; Trivedi, S; Casneuf, T; Krevvata, M; Ukropec, J; Kobos, R; Avet-Loiseau, H; Usmani, SZ; San-Miguel, J

View PubMed

LEUKEMIA 2020 10.1038/s41375-020-01060-w Clinical features and survival outcomes in IgD myeloma a study by Asia Myeloma Network (AMN) Liu¹, J; Hu, XX; Jia, YC; Lu, J; Lee, JH; Kim, K; Chen, WM; Liu, AJ; Liu, Y; Chen, Q; Zhang, CY; Suh, C; Kim, MK; Zhou, F; Chng, WJ; Kumar, SK; Durie, B; Hou, J; Fu, WJ; Du, J

View PubMed

INT J HEMATOL 2020 10.1007/s12185-020-02988-6 Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone Lee¹, HS; Kim, K; Lee, JJ; Yoon, SS; Bang, SM; Kim, JS; Eom, HS; Yoon, DH; Lee, YJ; Shin, HJ; Park, Y; Jo, JC; Lee, WS; Do, YR; Mun, YC; Lee, MH; Kim, HJ; Kim, SH; Kim, MK; Lim, SN; Park, SK; Yi, JH; Lee, JH; Min, CK

View PubMed

PATIENT EDUC COUNS 2020 10.1016/j.pec.2020.03.007 Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners Kim¹, IR; Jang, SY; Shin, HS; Choi, HJ; Jung, CW; Yoon, SS; Kim, JS; Kim, SJ; Kim, K; Kim, WS; Lee, CH; Kang, D; Cho, J

View PubMed

BMC CANCER 2020 10.1186/s12885-020-07317-y Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma Song¹, GY; Jung, SH; Kim, K; Kim, SJ; Yoon, SE; Lee, HS; Kim, M; Ahn, SY; Ahn, JS; Yang, DH; Kim, HJ; Lee, JJ

View PubMed

INT J HEMATOL 2020 10.1007/s12185-020-02869-y Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea the KMM1807 study Jung¹, J; Choi, YS; Lee, JH; Lee, WS; Kim, SH; Park, Y; Lee, SS; Do, YR; Jo, JC; Lee, JJ; Kim, JS; Shin, HJ; Shin, DY; Yoon, SS; Min, CK; Kim, K; Eom, HS

View PubMed

CLIN CANCER RES 2020 10.1158/1078-0432.CCR-19-0694 Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion Ryu¹, D; Kim, SJ; Hong, Y; Jo, A; Kim, N; Kim, HJ; Lee, HO; Kim, K; Park, WY

View PubMed

ANN HEMATOL 2020 10.1007/s00277-019-03904-7 The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) Jo¹, JC; Lee, HS; Kim, K; Lee, JJ; Yoon, SS; Bang, SM; Kim, JS; Eom, HS; Yoon, DH; Lee, Y; Shin, HJ; Park, Y; Lee, WS; Do, YR; Mun, YC; Lee, MH; Kim, HJ; Kim, SH; Kim, MK; Lim, SN; Cho, SH; Park, SK; Yi, JH; Lee, JH; Kim, J; Min, CK

View PubMed

J AM COLL CARDIOL 2020 10.1016/j.jacc.2019.11.045 Prognostic Value of the Index of Microcirculatory Resistance Over Serum Biomarkers in Cardiac Amyloidosis Choi¹, KH; Lee, JM; Kim, SR; Kim, D; Choi, JO; Kim, SJ; Kim, K; Kim, JS; Koo, BK; Jeon, ES

View PubMed

CLIN LYMPHOMA MYELOMA LEUK 2020 10.1016/j.clml.2019.10.017 Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study Jung¹, KS; Kim, K; Kim, HJ; Kim, SH; Lee, JO; Kim, JS; Lee, JJ; Eom, HS; Min, CK; Shin, HJ

View PubMed

MEDICINE 2020 10.1097/MD.0000000000018905 Tc-99m-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis Potential clinical implications Lee¹, JH; Kim, K; Choi, JO; Kim, SJ; Jeon, ES; Choi, JY

View PubMed

ANN LAB MED 2020 10.3343/alm.2020.40.1.88 Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults Choi¹, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES

View PubMed

AM J HEMATOL 2020 10.1002/ajh.25726 Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study) Lee¹, HS; Kim, K; Kim, SJ; Lee, JJ; Kim, I; Kim, JS; Eom, HS; Yoon, DH; Suh, C; Shin, HJ; Mun, YC; Kim, MK; Lim, SN; Choi, CW; Kang, HJ; Yoon, SS; Min, CK

View PubMed

LEUKEMIA 2020 10.1038/s41375-020-0711-6 Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Bahlis¹, NJ; Dimopoulos, MA; White, DJ; Benboubker, L; Cook, G; Leiba, M; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Kaufman, JL; Krevvata, M; Chiu, C; Qin, X; Okonkwo, L; Trivedi, S; Ukropec, J; Qi, M; San-Miguel, J

View PubMed

LEUKEMIA 2020 10.1038/s41375-019-0539-0 A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial Facon¹, T; Dimopoulos, MA; Meuleman, N; Belch, A; Mohty, M; Chen, WM; Kim, K; Zamagni, E; Rodriguez-Otero, P; Renwick, W; Rose, C; Tempescul, A; Boyle, E; Manier, S; Attal, M; Moreau, P; Macro, M; Leleu, X; Chretien, ML; Ludwig, H; Guo, S; Sturniolo, M; Tinel, A; Monzini, MS; Costa, B; Houck, V; Hulin, C; Mary, JY

View PubMed

IMMUNOL LETT 2019 10.1016/j.imlet.2019.10.005 A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model Hong¹, SH; Kim, K; Shin, JS; Chung, H; Park, CG

View PubMed

BONE MARROW TRANSPL 2019 10.1038/s41409-019-0629-7 Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma Lee¹, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

View PubMed

Blood Cancer J 2019 10.1038/s41408-019-0245-1 Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network Soekojo¹, CY; Kim, K; Huang, SY; Chim, CS; Takezako, N; Asaoku, H; Kimura, H; Kosugi, H; Sakamoto, J; Gopalakrishnan, SK; Nagarajan, C; Wei, Y; Moorakonda, R; Lee, SL; Lee, JJ; Yoon, SS; Kim, JS; Min, CK; Lee, JH; Durie, B; Chng, WJ

View PubMed

J CLIN APHERESIS 2019 10.1002/jca.21734 Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma Park¹, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ

View PubMed

EUR J CANCER CARE 2019 10.1111/ecc.13089 Influence of time lapse after cancer diagnosis on the association between unmet needs and quality of life in family caregivers of Korean cancer patients Shin¹, J; Ko, H; Lee, JW; Kim, K; Song, YM

View PubMed

SCI REP-UK 2019 10.1038/s41598-019-48513-6 Prognostic values of novel biomarkers in patients with AL amyloidosis Kim¹, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES

View PubMed

BIOL BLOOD MARROW TR 2019 10.1016/j.bbmt.2019.03.016 A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study Park¹, SS; Kim, K; Kim, SJ; Lee, JH; Yoon, SS; Mun, YC; Lee, JJ; Eom, HS; Kim, JS; Min, CK

View PubMed

SCI REP-UK 2019 10.1038/s41598-019-44245-9 Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis Kim¹, D; Lee, GY; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

View PubMed

ANN HEMATOL 2019 10.1007/s00277-019-03602-4 Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries Hungria¹, VTM; Lee, JH; Maiolino, A; Crusoe, ED; Martinez, G; Bittencourt, R; Duarte, GO; Fantl, DB; Navarro, JR; Conte, G; Gomez-Almaguer, D; Ruiz-Arguelles, GJ; Kim, K; Shimizu, K; Chen, WM; Huang, SY; Chng, WJ; Chim, CS; Nawarawong, W; Durie, B

View PubMed

Oncoimmunology 2019 10.1080/2162402X.2018.1544442 PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer Angell¹, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E

View PubMed

INT J HEMATOL 2019 10.1007/s12185-018-2540-1 Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone Shin¹, J; Lee, JJ; Kim, K; Min, CK; Lee, JO; Suh, C; Kim, JS; Lee, YJ; Yoon, SS; Jo, JC; Lee, HS; Bang, SM; Lee, JO; Bang, SM; Lee, JJ; Kim, K; Min, CK; Suh, C; Yoon, DH; Kim, JS; Lee, YJ; Moon, JH; Yoon, SS; Kim, I; Jo, JC; Lee, HS; Park, SK; Shin, HJ; Kim, MK; Mun, YC; Lee, MH; Park, Y; Eom, HS; Kim, HJ; Im, SN; Kim, SH; Do, YR; Lee, WS; Cho, SH; Yi, JH; Lee, JH

View PubMed

JPN J CLIN ONCOL 2019 10.1093/jjco/hyy177 Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice Park¹, SS; Eom, HS; Kim, JS; Koh, Y; Choi, CW; Lee, JJ; Kim, K; Suh, C; Lee, JH; Min, CK

View PubMed

ANN LAB MED 2019 10.3343/alm.2019.39.1.96 First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism Kim¹, H; Kim, K; Cho, SR; Kim, HJ; Kim, SH

View PubMed

J CLIN MICROBIOL 2018 10.1128/JCM.00438-18 Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients Ryu¹, MR; Park, MS; Cho, EH; Jung, CW; Kim, K; Kim, SJ; Oh, HY; Huh, W; Jang, HR; Koh, WJ; Park, HY; Kim, YH; Sinn, DH; Choi, JO; Joh, JW; Kim, JM; Kim, SJ; Park, JB; Kang, ES

View PubMed

HAEMATOL-HEMATOL J 2018 10.3324/haematol.2018.194282 Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX Dimopoulos¹, MA; San-Miguel, J; Belch, A; White, D; Benboubker, L; Cook, G; Leiba, M; Morton, J; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Kaufman, JL; Sutherland, HJ; Lalancette, M; Magen, H; Iida, S; Kim, JS; Prince, HM; Cochrane, T; Oriol, A; Bahlis, NJ; Chari, A; O'Rourke, L; Wu, K; Schecter, JM; Casneuf, T; Chiu, C; Soong, D; Sasser, AK; Khokhar, NZ; Avet-Loiseau, H; Usmani, SZ

View PubMed

ACTA HAEMATOL-BASEL 2018 10.1159/000490488 The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma Lee¹, GW; Park, SW; Go, SI; Kim, HG; Kim, MK; Min, CK; Kwak, JY; Bae, SB; Yoon, SS; Lee, JJ; Kim, KH; Nam, SH; Mun, YC; Kim, HJ; Bae, SH; Shin, HJ; Lee, JH; Park, JS; Jeong, SH; Lee, MH; Lee, HS; Park, KW; Lee, WS; Lee, SM; Lee, JO; Hyun, MS; Jo, DY; Lim, SN; Lee, JH; Kim, H; Cho, DY; Do, YR; Kim, JA; Park, SK; Kim, JS; Kim, SJ; Yi, HG; Moon, JH; Choi, CW; Kim, SH; Kim, BS; Park, MR; Shim, H; Song, MK; Kim, Y; Kim, K

View PubMed

LEUKEMIA LYMPHOMA 2018 10.1080/10428194.2018.1427858 Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop Tan¹, D; Lee, JH; Chen, WM; Shimizu, K; Hou, J; Suzuki, K; Nawarawong, W; Huang, SY; Chim, CS; Kim, K; Kumar, L; Malhotra, P; Chng, WJ; Durie, B

View PubMed

GENOME RES 2018 10.1101/gr.228080.117 Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data Fan¹, J; Lee, HO; Lee, S; Ryu, DE; Lee, S; Xue, C; Kim, SJ; Kim, K; Barkas, N; Park, PJ; Park, WY; Kharchenko, PV

View PubMed

BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5 Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study Yoo¹, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

View PubMed

BRIT J HAEMATOL 2018 10.1111/bjh.14701 A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System Jung¹, SH; Kim, K; Kim, JS; Kim, SJ; Cheong, JW; Kim, SJ; Ahn, JS; Ahn, SY; Yang, DH; Kim, HJ; Lee, JJ

View PubMed

BIOL BLOOD MARROW TR 2018 10.1016/j.bbmt.2018.01.004 Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) Jung¹, SH; Lee, JJ; Kim, JS; Min, CK; Kim, K; Choi, Y; Eom, HS; Joo, YD; Kim, SH; Kwak, JY; Kang, HJ; Lee, JH; Lee, HS; Mun, YC; Moon, JH; Sohn, SK; Park, SK; Park, Y; Shin, HJ; Yoon, SS

View PubMed

KOREAN J RADIOL 2018 10.3348/kjr.2018.19.3.481 Prognostic Value of Baseline F-18-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study Moon¹, SH; Choi, WH; Yoo, IR; Lee, SJ; Paeng, JC; Jeong, SY; Lee, SW; Kim, K; Choi, JY

View PubMed

ANN LAB MED 2018 10.3343/alm.2018.38.3.196 Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience Jung¹, HA; Jang, MA; Kim, K; Kim, SH

View PubMed

PROTEOM CLIN APPL 2018 10.1002/prca.201700106 Development and Validation of Mass Spectrometry-Based Targeted Analysis for Amyloid Proteins Park¹, J; Lee, GY; Choi, JO; Jeon, ES; Kim, K; Kim, JS; Lee, SY

View PubMed

ANN ONCOL 2018 10.1093/annonc/mdy034 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim¹, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J

View PubMed

AM J HEMATOL 2017 10.1002/ajh.24891 Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy Cho¹, H; Yoon, DH; Lee, JB; Kim, SY; Moon, JH; Do, YR; Lee, JH; Park, Y; Lee, HS; Eom, HS; Shin, HJ; Min, CK; Kim, JS; Jo, JC; Kang, HJ; Mun, YC; Lee, WS; Lee, JJ; Suh, C; Kim, K

View PubMed

JPN J CLIN ONCOL 2017 10.1093/jjco/hyx120 Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy Park¹, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K

View PubMed

LEUKEMIA 2017 10.1038/leu.2017.138 Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study Kumar¹, SK; Dimopoulos, MA; Kastritis, E; Terpos, E; Nahi, H; Goldschmidt, H; Hillengass, J; Leleu, X; Beksac, M; Alsina, M; Oriol, A; Cavo, M; Ocio, EM; Mateos, MV; O'Donnell, EK; Vij, R; Lokhorst, HM; van de Donk, NWCJ; Min, C; Mark, T; Turesson, I; Hansson, M; Ludwig, H; Jagannath, S; Delforge, M; Kyriakou, C; Hari, P; Mellqvist, U; Usmani, SZ; Dytfeld, D; Badros, AZ; Moreau, P; Kim, K; Otero, PR; Lee, JH; Shustik, C; Waller, D; Chng, WJ; Ozaki, S; Lee, JJ; de la Rubia, J; Eom, HS; Rosinol, L; Lahuerta, JJ; Sureda, A; Kim, JS; Durie, BGM

View PubMed

Clin Transl Oncol 2017 10.1007/s12094-017-1662-x Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma Cho¹, J; Kim, SY; Kim, YJ; Sim, MH; Kim, ST; Kim, NKD; Kim, K; Park, W; Kim, JH; Jang, KT; Lee, J

View PubMed

ONCOTARGET 2017 10.18632/oncotarget.18535 The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160) Jung¹, SH; Lee, JJ; Kim, K; Suh, C; Yoon, DH; Min, CK; Sohn, SK; Choi, CW; Lee, HS; Kim, HJ; Shin, HJ; Bang, SM; Yoon, SS; Park, SK; Yhim, HY; Kim, MK; Jo, JC; Mun, YC; Lee, JH; Kim, JS

View PubMed

Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25. Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma Kim HS1¹, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

View PubMed

Br J Haematol. 2017 Mar;176(5):743-749. doi: 10.1111/bjh.14465. Epub 2017 Jan 20. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial Lu J1¹, Lee JH2, Huang SY3, Qiu L4, Lee JJ5, Liu T6, Yoon SS7, Kim K8, Shen ZX9, Eom HS10, Chen WM11, Min CK12, Kim HJ13, Lee JO14, Kwak JY15, Yiu W16, Chen G16, Ervin-Haynes A16, Hulin C17, Facon T18.

View PubMed

Cancer Med. 2017 Jan;6(1):100-108. doi: 10.1002/cam4.970. Epub 2016 Dec 1. Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study Kwon J1¹, Min CK2, Kim K3, Han JJ4, Moon JH5, Kang HJ6, Eom HS7, Kim MK8, Kim HJ9, Yoon DH10, Lee JO11, Lee WS12, Lee JH13, Lee JJ14, Choi YS15, Kim SH16, Yoon SS17.

View PubMed

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

View PubMed

Oncotarget. 2016 Oct 18;7(42):68350-68359. doi: 10.18632/oncotarget.12029. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis Kim SJ1¹, Shin HT2, Lee HO2, Kim NK2, Yun JW2, Hwang JH3, Kim K1, Park WY2.

View PubMed

Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988. Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

View PubMed

BMC Cancer. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen Jung SH1¹, Cho MS1, Kim HK2, Kim SJ2, Kim K3, Cheong JW4, Kim SJ4, Kim JS4, Ahn JS1, Kim YK1, Yang DH1, Kim HJ1, Lee JJ5; Korean Multiple Myeloma Working Party (KMMWP).

View PubMed

Oncotarget. 2016 Jul 26;7(30):47127-47133. doi: 10.18632/oncotarget.9478. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker Ryu D1¹,2, Kim HJ3, Joung JG1, Lee HO1,4, Bae JS1, Kim SJ5, Kim H5, Park WY1,2,4, Kim K5.

View PubMed

Ann Hematol. 2016 May;95(6):911-9. doi: 10.1007/s00277-016-2660-8. Epub 2016 Apr 6. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea Lee HS1¹, Min CK2, Lee JJ3, Kim K4, Kim SJ4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13, Lee MH14

View PubMed

J Infect. 2016 Feb;72(2):233-9. doi: 10.1016/j.jinf.2015.10.014. Epub 2015 Nov 26. Multiple myeloma as a major cause of false-positive galactomannan tests in adult patients with cancer Ko JH1¹, Peck KR2, Lee JY1, Cho SY1, Ha YE1, Kang CI1, Chung DR1, Kim K3, Kang ES4, Song JH1.

View PubMed

Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10. Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis Lim SH1¹, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.

View PubMed

Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients Park S1¹, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.

View PubMed

J Clin Lab Anal. 2015 Nov;29(6):505-10. doi: 10.1002/jcla.21801. Epub 2014 Oct 2. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma Shin SY1¹, Lee ST1, Kim HJ1, Kim SJ2, Kim K2, Kang ES1, Kim SH1.

View PubMed

Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12. Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy Lee JY1¹, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.

View PubMed

Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26. Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma Park S1¹, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.

View PubMed

Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25. KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.

View PubMed

J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study Gupta N1¹, Goh YT2, Min CK3, Lee JH4, Kim K5, Wong RS6, Chim CS7, Hanley MJ8, Yang H9, Venkatakrishnan K10, Hui AM11, Esseltine DL12, Chng WJ13,14.

View PubMed

Korean J Intern Med. 2015 Sep;30(5):675-83. doi: 10.3904/kjim.2015.30.5.675. Epub 2015 Aug 28. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea Kim C1¹, Lee HS1, Min CK2, Lee JJ3, Kim K4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13.

View PubMed

Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia Kim DY¹, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology.

View PubMed

Korean J Intern Med. 2015 Jul;30(4):496-505. doi: 10.3904/kjim.2015.30.4.496. Epub 2015 Jun 29. Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience Lim AY1¹, Lee JH1, Jung KS1, Gwag HB1, Kim do H1, Kim SJ1, Lee GY1, Kim JS2, Kim HJ3, Lee SY3, Lee JE1, Jeon ES1, Kim K1.

View PubMed

Anticancer Res. 2015 May;35(5):3081-9. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome Hong JY1¹, Seo JY2, Kim SH3, Jung HA4, Park S4, Kim K4, Jung CW4, Kim JS5, Park JS6, Kim HJ7, Jang JH8.

View PubMed

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35. doi: 10.1016/j.clml.2014.12.007. Epub 2014 Dec 12. The t(11;14)(q13;q32) Trans location as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma Shin HJ1¹, Kim K2, Lee JJ3, Song MK1, Lee EY4, Park SH4, Kim SH5, Jang MA5, Kim SJ6, Chung JS1.

View PubMed

Ann Hum Genet. 2015 Mar;79(2):99-107. doi: 10.1111/ahg.12101. Epub 2015 Jan 23. Asp58Ala is the Predominant Mutation of the TTR Gene in Korean Patients with Hereditary Transthyretin-Related Amyloidosis Jang MA1¹, Lee GY, Kim K, Kim SJ, Kim JS, Lee SY, Kim HJ, Jeon ES.

View PubMed

Amyloid. 2014 Dec;21(4):261-6. doi: 10.3109/13506129.2014.960560. Epub 2014 Sep 24. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis Lee JY1¹, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

View PubMed

Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience Lee KH1¹, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.

View PubMed

Eur J Haematol. 2014 Nov;93(5):414-21. doi: 10.1111/ejh.12377. Epub 2014 Jun 14. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma Shin HJ1¹, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS.

View PubMed

Support Care Cancer. 2014 Oct;22(10):2669-75. doi: 10.1007/s00520-014-2256-6. Epub 2014 Apr 26. Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients Cho J1¹, Kang D, Lee JY, Kim K, Kim SJ.

View PubMed

Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7. Spinal cord compression in multiple myeloma: a single center experience Jung HA1¹, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.

View PubMed

Ann Hematol. 2014 Sep;93(9):1571-7. doi: 10.1007/s00277-014-2067-3. Epub 2014 Apr 12. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study Ahn SY1¹, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ; Korean Multiple Myeloma Working Party.

View PubMed

Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study Oh S1¹, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).

View PubMed

Acta Haematol. 2014;132(2):226-32. Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation Chang WJ¹, Kang ES, Lee ST, Kim SH, Kim DW, Kim SJ, Kim K.

View PubMed

Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study Oh S1¹, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).

View PubMed

Anticancer Res. 2014 Aug;34(8):4299-306. Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement Park S1¹, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

View PubMed

Am J Hematol. 2014 Jul;89(7):751-6. doi: 10.1002/ajh.23731. Epub 2014 Apr 26. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study Kim K1¹, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim CS, Nawarawong W, Siritanaratkul N, Durie BG.

View PubMed

Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10. Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma Kim SM1¹, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

View PubMed

Biomed Res Int. 2014;2014:253243. doi: 10.1155/2014/253243. Epub 2014 Jun 4. Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenstrom Macroglobulinemia in Korea Lee HS1¹, Kim K2, Yoon DH3, Kim JS4, Bang SM5, Lee JO5, Eom HS6, Lee H6, Kim I7, Lee WS8, Bae SH9, Kim SH10, Lee MH11, Do YR12, Lee JH13, Hong J13, Shin HJ14, Lee JH15, Mun YC16, Min CK17.

View PubMed

Mayo Clin Proc.?2014 Jun;89(6):781-9. doi: 10.1016/j.mayocp.2014.01.013. Epub 2014 Apr 3. Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness Lee GY1¹,?Kim K2,?Choi JO1,?Kim SJ2,?Kim JS3,?Choe YH4,?Grogan MA5,?Jeon ES6.

View PubMed

Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26. Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients Park S1¹, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.

View PubMed

Ann Hematol. 2014 Apr;93(4):603-8. doi: 10.1007/s00277-013-1915-x. Epub 2013 Oct 19. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts Seo JY1¹, Lee KO, Kim SH, Kim K, Jung CW, Jang JH, Kim HJ.

View PubMed

Br J Haematol. 2014 Mar;164(5):745-8. doi: 10.1111/bjh.12670. Epub 2013 Nov 18. Central nervous system multiple myeloma: a different cytogenetic profile Chang WJ1¹, Kim SJ, Kim K.

View PubMed

Anticancer Res. 2014 Feb;34(2):1037-45. Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia Jung HA1¹, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.

View PubMed

Ann Hematol. 2014 Jan;93(1):113-21. doi: 10.1007/s00277-013-1893-z. Epub 2013 Sep 12. Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients Kim K1¹, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP).

View PubMed

Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents Park S1¹, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.

View PubMed

Amyloid. 2013 Dec;20(4):204-11. doi: 10.3109/13506129.2013.824417. Epub 2013 Aug 5. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea Kim SJ1¹, Lee GY, Jang HR, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

View PubMed

Leuk Res. 2013 Sep;37(9):1070-6. doi: 10.1016/j.leukres.2013.06.008. Epub 2013 Jun 28. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network Tan D1¹, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, Goh YT, Durie BG, Chng WJ, Lee JH.

View PubMed

Bone Marrow Transplant. 2013 Mar;48(3):425-32. doi: 10.1038/bmt.2012.164. Epub 2012 Sep 3. Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT Yhim HY1¹, Kim K, Kim JS, Kang HJ, Kim JA, Min CK, Bae SH, Park E, Yang DH, Suh C, Kim MK, Mun YC, Eom HS, Shin HJ, Yoon HJ, Kwon JH, Lee JH, Kim YS, Yoon SS, Kwak JY.

View PubMed

Am J Hematol. 2013 Jan;88(1):52-5. doi: 10.1002/ajh.23333. Epub 2012 Oct 1. Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: Results of multicenter analysis Jun HJ1¹, Kim K, Kim SJ, Mun YC, Bang SM, Won JH, Kim CS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).

View PubMed

J Korean Med Sci. 2013 Jan;28(1):80-6. doi: 10.3346/jkms.2013.28.1.80. Epub 2013 Jan 8. Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation Lee HS1¹, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS; Korean Multiple Myeloma Working Party (KMMWP).

View PubMed

Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):118-26. doi: 10.1016/j.clml.2011.11.002. Epub 2011 Dec 28. Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma Teoh G1¹, Chen Y, Kim K, Srivastava A, Pai VR, Yoon SS, Suh C, Kim YK.

View PubMed

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial Kim HJ1¹, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

View PubMed

Am J Hematol. 2012 Jan;87(1):37-41. doi: 10.1002/ajh.22193. Epub 2011 Nov 25. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity Ahn HK1¹, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH.

View PubMed

Biol Blood Marrow Transplant. 2011 Nov;17(11):1630-7. doi: 10.1016/j.bbmt.2011.04.006. Epub 2011 Apr 23. Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus Park S1¹, Kim K, Kim DH, Jang JH, Kim SJ, Kim WS, Jung CW, Koh KC.

View PubMed

Jpn J Clin Oncol. 2011 Mar;41(3):353-7. doi: 10.1093/jjco/hyq194. Epub 2010 Oct 14. Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study Kim SJ1¹, Kim K, Do YR, Bae SH, Yang DH, Lee JJ.

View PubMed

Ann Oncol. 2011 Feb;22(2):411-6. doi: 10.1093/annonc/mdq393. Epub 2010 Aug 2. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients Kim MK1¹, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH; Korean Multiple Myeloma Working Party.

View PubMed

Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety Lee SS1¹, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

View PubMed

Int J Hematol. 2010 Jul;92(1):52-7. doi: 10.1007/s12185-010-0617-6. Epub 2010 Jun 11. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party Lee JH1¹, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, Bang SM, Kim HJ, Kim JS, Kim K, Eom HS, Min CK, Yoon SS, Kim SH, Suh C, Cho KS; Korean Multiple Myeloma Working Party.

View PubMed

Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8. A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation Kim ST1¹, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.

View PubMed

Ann Hematol. 2010 May;89(5):489-97. doi: 10.1007/s00277-009-0871-y. Epub 2009 Dec 10. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) Eom HS1¹, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH.

View PubMed

Br J Haematol. 2010 May;149(4):537-49. doi: 10.1111/j.1365-2141.2010.08127.x. Epub 2010 Mar 12. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo Kim K1¹, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.

View PubMed

Cancer Genet Cytogenet. 2010 Mar;197(2):117-21. doi: 10.1016/j.cancergencyto.2009.11.008. Molecular cytogenetic analysis of Korean patients with Waldenstrom macroglobulinemia Bang SM1¹, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, Cho SR, Kim HC, Song J, Kim JS, Kim KH, Lee JH, Lee JJ, Shin MG, Suh C, Chi HS, Oh DY, Won JH, Kim HJ, Yoon SS, Lee DS; Korean Multiple Myeloma Working Party (KMMWP).

View PubMed

Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients Moon JH1¹, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.

View PubMed

Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide Koh Y1¹, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party.

View PubMed

J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16. Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Choi ER1¹, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.

View PubMed

Transplantation. 2009 Dec 27;88(12):1349-59. doi: 10.1097/TP.0b013e3181bd7b3a. Bortezomib Can Suppress Activation of Rapamycin-Resistant Memory T Cells Without Affecting Regulatory T-Cell Viability in Non-Human Primates Kim JS1¹, Lee JI, Shin JY, Kim SY, Shin JS, Lim JH, Cho HS, Yoon IH, Kim KH, Kim SJ, Park CG.

View PubMed

Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29. Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry Kim SJ1¹, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim BS, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

View PubMed

Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells Tai YT1¹, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC.

View PubMed

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512. Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation Kim JS1¹, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

View PubMed

J Korean Med Sci. 2008 Apr;23(2):278-83. doi: 10.3346/jkms.2008.23.2.278. Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia Han AR1¹, Kim K, Jang JH, Kim WS, Ahn JS, Jung CW, Lee MH, Kang WK.

View PubMed

Cancer Lett. 2007 Dec 8;258(1):90-7. Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study Oh SY1¹, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ.

View PubMed

Eur J Haematol. 2007 Oct;79(4):287-91. Epub 2007 Aug 10. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease Oh SY1¹, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ.

View PubMed

Biol Blood Marrow Transplant. 2007 Apr;13(4):463-8. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation Uhm JE1¹, Kim K, Lim TK, Park BB, Park S, Hong YS, Lee SC, Hwang IG, Koh KC, Lee MH, Ahn JS, Kim WS, Jung CW, Kang WK.

View PubMed

Leuk Lymphoma. 2006 Oct;47(10):2128-31. High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population Cho JH1¹, Park YH, Kim WS, Oh SY, Cho SI, Kang HJ, Na II, Ryoo BY, Yang SH, Kim K, Jung CW, Park K, Ko YH, Lee SS.

View PubMed

Biol Blood Marrow Transplant. 2006 Aug;12(8):837-44. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy Kim H1¹, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, Kim DH, Sohn SK, Lee JJ, Suh C.

View PubMed

Int J Hematol. 2006 May;83(4):309-13. A Multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma Bang SM1¹, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS; Korean Multiple Myeloma Working Party.

View PubMed

Ann Hematol. 2006 May;85(5):285-90. Epub 2006 Mar 4. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia Park YH1¹, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH.

View PubMed

Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH1¹, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.

View PubMed

Br J Haematol. 2005 Oct;131(1):59-66. Effects of nuclear factor-kappa B inhibitors and its implication on natural killer T-cell lymphoma cells Kim K1¹, Ryu K, Ko Y, Park C.

View PubMed

J Cell Biochem. 2005 Mar 1;94(4):695-707. Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60 Han SS1¹, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.

View PubMed

Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission Lee SH1¹, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.

View PubMed

Cell Signal. 2005 Jan;17(1):111-9. Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells Park S1¹, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.

View PubMed

Int J Biochem Cell Biol. 2004 Nov;36(11):2180-95. L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms Park S1¹, Han SS, Park CH, Hahm ER, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Kimler BF, Kim K, Lee JH.

View PubMed

J Cell Biochem. 2004 Oct 1;93(2):257-70. L-ascorbic acid represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60 Han SS1¹, Kim K, Hahm ER, Lee SJ, Surh YJ, Park HK, Kim WS, Jung CW, Lee MH, Park K, Yang JH, Yoon SS, Riordan NH, Riordan HD, Kimler BF, Park CH, Lee JH, Park S.

View PubMed

Primary pulmonary non-Hodgkin's lymphoma

Transfusion. 2004 Apr;44(4):533-8. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses Suh C1¹, Kim HJ, Kim SH, Kim S, Lee SJ, Lee YS, Kim EK, Kim SB, Lee JS, Kim MW, Kim K, Yoon SS.

View PubMed

Bone Marrow Transplant. 2003 Nov;32(9):889-95. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J1¹, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.

View PubMed

Am J Hematol. 2002 Oct;71(2):75-9. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies Kim K1¹, Lee MH, Kim J, Lee KS, Kim SM, Jung MP, Han J, Sung KW, Kim WS, Jung CW, Yoon SS, Im YH, Kang WK, Park K, Park CH.

View PubMed

Am J Clin Oncol. 2002 Aug;25(4):354-7. Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer Kim K1¹, Nam E, Lee NS, Lee HR, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY, Park JO, Kim WS, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH, Park K, Kang WK.

View PubMed

Eur J Cancer. 2002 Jan;38(1):75-81. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification Kim K1¹, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K.

View PubMed

날짜						금 01	토 02	일 03	월 04	화 05	수 06	목 07	금 08	토 09	일 10	월 11	화 12	수 13	목 14	금 15	토 16	일 17	월 18	화 19	수 20	목 21	금 22	토 23	일 24	월 25	화 26	수 27	목 28	금 29	토 30
오전
오후

날짜	일 01	월 02	화 03	수 04	목 05	금 06	토 07	일 08	월 09	화 10	수 11	목 12	금 13	토 14	일 15	월 16	화 17	수 18	목 19	금 20	토 21	일 22	월 23	화 24	수 25	목 26	금 27	토 28	일 29	월 30	화 31
오전
오후

게재일	2014-10-22
발표년월	2012-05	구분	국내
학술지	가정의학회지
논문명(국문)
논문명(영문)
요약문	td	발행정보	2010;31(10):778-785
책임저자	이정권
저자	박주현, 이선진, 곽정임, 심재용, 이정권	제 1저자	박주현
초록첨부	test
논문첨부

혈액종양내과 김기현 교수

학력

경력

[언론기사]

[기고] 다발골수종 치료의 패러다임 변화를 기대하며

[언론기사]

발전하는 다발골수종 치료, 적극적인 재발 관리로 완치 기대

[언론기사]

신약 못 쓰는 애타는 암환자…건강보험 적용 사실상 불가능

[언론기사]

건강교실 '성인 혈액암 최신 치료법'

[TV&동영상]

신경통인줄 알았는데...'노인 백혈병' 다발 골수종

[언론기사]

50대 이상 ‘빈혈·출혈·뼈 통증’ 복합 증상 땐 골수암 의심을

[언론기사]

다발골수종의 효과적인 치료를 위한 약물요법의 선택

[언론기사]

[청년의사]의료진들, 레블리미드 급여화에 너도나도 반색